NovaBridge Biosciences (NBP) Operating Expenses (2019 - 2025)
NovaBridge Biosciences (NBP) posted quarterly Operating Expenses of -$72.9 million for Q4 2025, down 445.21% year-over-year from $21.1 million in Q4 2024, and down 710.99% quarter-over-quarter from -$9.0 million in Q3 2025.
NovaBridge Biosciences (NBP) Operating Expenses (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Operating Expenses for 5 consecutive years, with -$72.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Expenses fell 445.21% year-over-year to -$72.9 million; the TTM figure through Dec 2025 stood at -$94.3 million (down 83.31% YoY), while the FY2025 annual figure was -$94.3 million, down 83.31% from the prior year.
- Operating Expenses retreated to -$72.9 million in Q4 2025 per NBP's latest filing, from -$9.0 million in the prior quarter.
- Across five years, Operating Expenses topped out at -$5.3 million in Q1 2025 and bottomed at -$72.9 million in Q4 2025.
- Historically, Operating Expenses has averaged -$17.4 million across 3 years, with a median of -$10.9 million in 2023.
- On a YoY basis, Operating Expenses climbed as much as 58.49% in 2025 and fell as far as 445.21% in 2025.
- NovaBridge Biosciences' Operating Expenses stood at -$10.9 million in 2023, then slipped by 22.12% to -$13.4 million in 2024, then plunged by 445.21% to -$72.9 million in 2025.
- Business Quant data shows NBP's Operating Expenses at -$72.9 million in Q4 2025, -$9.0 million in Q3 2025, and -$7.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | NovaBridge Biosciences | 215.85 Mn | 215.85 Mn | - | -72.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.90 Mn |
| Sep 30, 2025 | -8.99 Mn |
| Jun 30, 2025 | -7.11 Mn |
| Mar 31, 2025 | -5.27 Mn |
| Dec 31, 2024 | -13.37 Mn |
| Sep 30, 2024 | -12.41 Mn |
| Jun 30, 2024 | -17.14 Mn |
| Mar 31, 2024 | -8.50 Mn |
| Sep 30, 2023 | -10.95 Mn |
| Dec 31, 2020 | 318.34 Mn |
| Sep 30, 2020 | -145.72 Mn |
| Dec 31, 2019 | 261.55 Mn |
| Sep 30, 2019 | -45.86 Mn |